KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial.

Julian D Gillmore, David Adams, Markus Weiler, Ahmad Masri, Laura Obici, Jonatan Nåtman, T Jesse Kwoh, Barry Reicher, James Revkin, Márcia Waddington Cruz, Morie Gertz, Chi-Chao Chao

Eur J Neurol 33(4) e70580

PMID41913562
PMCIDPMC13140992
DOI10.1111/ene.70580
发表日期2026-03-31
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:生活质量量表图;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: This exploratory analysis of the NEURO-TTRansform Phase 3 trial evaluated the efficacy of eplontersen in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy by genetic variant. METHODS: Changes from baseline in NEURO-TTRansform primary endpoints serum transthyretin (TTR) at Week 65, modified Neuropathy Impairment Score+7 (mNIS+7) composite score, and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score at Week 66 were evaluated in patients with early-onset (aged < 50 years) and late-onset (aged ≥ 50 years) Val30Met (p.Val50Met) or non-Val30Met ATTRv amyloidosis with polyneuropathy. Secondary endpoints from NEURO-TTRansform were also evaluated by genetic variant. RESULTS: In total, 144 patients with early-onset (n = 54) or late-onset (n = 31) Val30Met or non-Val30Met (n = 59), ATTRv amyloidosis with polyneuropathy were randomized to eplontersen. A further 60 patients from NEURO-TTR with early-onset (n = 16) or late-onset (n = 17) Val30Met or non-Val30Met (n = 27), served as a historical placebo group. The mean percentage difference (95% confidence interval) in serum TTR was -79.9 (-87.8, -72.0), -85.0 (-93.3, -76.6), and -70.6 (-77.7, -63.5) with eplontersen versus placebo in the early- and late-onset Val30Met, and non-Val30Met groups, respectively. Across subgroups, the change from baseline to Week 66 in mNIS+7 composite score was generally well maintained, and the Norfolk QoL-DN total score improved with eplontersen versus worsening with placebo. The Polyneuropathy Disability score was maintained in most patients. From baseline to Week 65, the modified body mass index was maintained with eplontersen compared to a marked reduction (worsening) for placebo. CONCLUSIONS: Findings were suggestive of consistent benefits in reducing neuropathy impairment and improving QoL with eplontersen versus historical placebo, across TTR variants. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04136184, NCT01737398.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Mean (95% CI) percentage change from baseline to Week 65 in serum TTR concentration by TTR variant. † From the NEURO‐TTR study. CI, confidence interval; Diff., difference in means; TTR, transthyretin.
非 KM Figure
FIGURE 2Mean (95% CI) change from baseline to Week 66 in (A) mNIS+7 composite score (higher scores indicate a worse health state) and (B) Norfolk QoL‐DN total score by TTR variant (higher scores indicate a worse health state). ‡ From the NEURO‐TTR study. CI, confidence interval; Diff., difference in means; mNIS+7, modified Neuropathy Impairment Score + 7; Norfolk QoL‐DN, Norfolk Quality of Life‐Diabetic Neuropathy; TTR, transthyretin.
非 KM Figure
FIGURE 3Change from baseline to Week 65/66 in (A) NSC (higher scores indicate a worse health state), (B) PCS of SF‐36, and (C) mBMI score by TTR variant. ‡ From the NEURO‐TTR study. Diff., difference in means; mBMI, modified body mass index; NSC, Neuropathy Symptom and Change; PCS of SF‐36, Physical Component Summary of Short Form‐36 questionnaire; TTR, transthyretin.
非 KM Figure
FIGURE 4Change in PND score at Week 65 by TTR variant. Imp., improved; NC, not changed; PND, Polyneuropathy Disability; TTR, transthyretin; Wor., worsened.
非 KM Figure